# A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

> **NCT02131064** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 444 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT02131064
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-25
- **Primary completion:** 2015-12-31
- **Final completion:** 2018-05-29
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131064, "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02131064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*